Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan

Pharmacoepidemiol Drug Saf. 2016 Feb;25(2):133-40. doi: 10.1002/pds.3890. Epub 2015 Nov 2.

Abstract

Purpose: Patients with psoriasis and/or psoriatic arthritis (PsA) are known to have increased cardiovascular morbidity and mortality. Hypertension, an important risk factor for cardiovascular disease, is highly prevalent in patients with psoriasis and/or PsA. The effects of anti-psoriatic medications - including cyclosporine, nonsteroidal anti-inflammatory drugs, and glucocorticoids - on hypertension remain unclear. We examined whether such medication exposure was associated with hypertension in psoriasis patients.

Methods: This population-based, nested case-control study analyzed data from an inception psoriasis cohort identified from Taiwan's National Health Insurance Research Database, 2000-2010. A total of 1530 patients with newly diagnosed hypertension and 4542 age- and gender-matched controls were included in the analysis. Conditional logistic regressions were applied to estimate the effects of drug of interest on hypertension.

Results: After adjusting for potential confounders, patients with current use of cyclosporine [odds ratio (OR) = 7.13; 95% confidence interval (CI) 1.85-27.49], nonsteroidal anti-inflammatory drugs (OR = 2.2; 95% CI 1.95-2.49), or systemic glucocorticoids (OR = 1.42; 95% CI 1.23-1.64) showed an increased risk of hypertension as compared to those not exposed to these drugs. Moreover, an increasing dose or combined use of nonsteroidal anti-inflammatory drugs and glucocorticoids was associated with increased hypertension risk. The risk of hypertension associated with glucocorticoids, or combined use was greatest among patients aged 49 years or less.

Conclusions: The use of cyclosporine, nonsteroidal anti-inflammatory drugs, or glucocorticoid was associated with hypertension in patients with psoriasis and/or PsA. These study results inform physicians on the importance of early identification of hypertension during therapy with such medication.

Keywords: Cyclosporine; Hypertension; Psoriasis; nonsteroidal anti-inflammatory drugs; pharmacoepidemiology; systemic glucocorticoids.

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Case-Control Studies
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects*
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / adverse effects
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • Humans
  • Hypertension / chemically induced*
  • Hypertension / epidemiology
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Population Surveillance* / methods
  • Psoriasis / drug therapy*
  • Psoriasis / epidemiology
  • Risk Factors
  • Taiwan / epidemiology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Dermatologic Agents
  • Glucocorticoids
  • Cyclosporine